CERT Certara, Inc.

Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies and academic institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

$26.11  -0.97 (-3.58%)
As of 12/03/2021 15:59:58 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/11/2020
Outstanding shares:  159,679,485
Average volume:  1,533,548
Market cap:   $4,324,120,454
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    15687V109
ISIN:        US15687V1098
Sedol:      BM9GT61
Valuation   (See tab for details)
PE ratio:   -71.84
PB ratio:   4.23
PS ratio:   15.70
Return on equity:   -5.97%
Net income %:   -21.07%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy